Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 2
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
2| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11738120 | DEFENCATHheparin sodium; taurolidine | substance, product | Apr 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| DEFENCATHHEPARIN SODIUM; TAUROLIDINE | GAIN Qualified infectious disease product (GAIN) | Nov 2033 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| DEFENCATH | taurolidine and heparin | solution, intraluminal | 72990-103NDA |
Enquiry
Common questions
- Is CorMedix Inc. FDA approved?
- CorMedix Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does CorMedix Inc. make?
- 1 product is listed under CorMedix Inc. in the openFDA NDC Directory, most often as solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.